Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II) : a national cohort study with nested test-negative design

Sheikh, AzizKerr, StevenWoolhouse, MarkMcMenamin, JimRobertson, ChrisEAVE II CollaboratorsSimpson, Colin RichardMillington, TristanShi, TingAgrawal, UtkarshHameed, Safraj ShahulHall, ElliottRudan, IgorShah, Syed AhmarRitchie, LewisStock, SarahMcCowan, Colin2022-06-242022-06-242022-07Sheikh, A, Kerr, S, Woolhouse, M, McMenamin, J, Robertson, C, EAVE II Collaborators, Simpson, C R, Millington, T, Shi, T, Agrawal, U, Hameed, S S, Hall, E, Rudan, I, Shah, S A, Ritchie, L, Stock, S & McCowan, C 2022, 'Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II) : a national cohort study with nested test-negative design', The Lancet Infectious Diseases, vol. 22, no. 7, pp. 959-966. https://doi.org/10.1016/S1473-3099(22)00141-41473-3099Bibtex: SHEIKH2022959https://hdl.handle.net/2164/18748This study is part of the EAVE II project. EAVE II is funded by the MRC (MC_PC_19075) with the support of BREATHE—The Health Data Research Hub for Respiratory Health (MC_PC_19004), which is funded through the UK Research and Innovation Industrial Strategy Challenge Fund and delivered through Health Data Research UK. This research is part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (MC_PC_20058). Additional support has been provided through Public Health Scotland, the Scottish Government Director General Health and Social Care, and the University of Edinburgh. The original EAVE project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme (11/46/23). The views expressed are those of the authors and not necessarily those of the NIHR, the Department of Health and Social Care, or the UK Government. We thank Dave Kelly from Albasoft (Inverness, UK) for his support with making primary care data available, and Wendy Inglis-Humphrey, Vicky Hammersley, and Laura Brook (University of Edinburgh, Edinburgh, UK) for their support with project management and administration.8622725engSDG 3 - Good Health and Well-beingR MedicineSupplementary DataRSeverity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II) : a national cohort study with nested test-negative designJournal article10.1016/S1473-3099(22)00141-4227